--
--(--)
--
--(--)
Expected P&L on Expiry
Key Stats
0.00DAY`S RANGE0.00
0.00
0.00
--
--
--
--
--
--
--
Pricing Model
--
--
--
--
--
--
About ALMS20260220P24
Biological Technology
Alumis Inc., a Delaware corporation, was incorporated on January 29, 2021. They are a clinical-stage biopharmaceutical company initially focused on developing two tyrosine kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor they are developing to achieve maximum targeted inhibition, and A-005, a central nervous system osmotic molecule. The company's mission is to significantly improve patients' lives by replacing broad immunosuppression with targeted therapy.
